key: cord-0917552-ka5cn6nn
authors: Forrestall, Katrina L.; Burley, Darcy E.; Cash, Meghan K.; Pottie, Ian R.; Darvesh, Sultan
title: 2-Pyridone natural products as inhibitors of SARS-CoV-2 main protease
date: 2020-12-02
journal: Chem Biol Interact
DOI: 10.1016/j.cbi.2020.109348
sha: 178d17e4729875381546afb4d8e2a9ae490e598a
doc_id: 917552
cord_uid: ka5cn6nn

The disease, COVID-19, is caused by the severe acute respiratory coronavirus 2 (SARS-CoV-2) for which there is currently no treatment. The SARS-CoV-2 main protease (M(pro)) is an important enzyme for viral replication. Small molecules that inhibit this protease could lead to an effective COVID-19 treatment. The 2-pyridone scaffold was previously identified as a possible key pharmacophore to inhibit SARS-CoV-2 M(pro). A search for natural, antimicrobial products with the 2-pyridone moiety was undertaken herein, and their calculated potency as inhibitors of SARS-CoV-2 M(pro) was investigated. Thirty-three natural products containing the 2-pyridone scaffold were identified from the literature. An in silico methodology using AutoDock was employed to predict the binding energies and inhibition constants (K(i) values) for each 2-pyridone-containing compound with SARS-CoV-2 M(pro). This consisted of molecular optimization of the 2-pyridone compound, docking of the compound with a crystal structure of SARS-CoV-2 M(pro), and evaluation of the predicted interactions and ligand-enzyme conformations. All compounds investigated bound to the active site of SARS-CoV-2 M(pro), close to the catalytic dyad (His-41 and Cys-145). Thirteen molecules had predicted K(i) values < 1 μM. Glu-166 formed a key hydrogen bond in the majority of the predicted complexes, while Met-165 had some involvement in the complex binding as a close contact to the ligand. Prominent 2-pyridone compounds were further evaluated for their ADMET properties. This work has identified 2-pyridone natural products with calculated potent inhibitory activity against SARS-CoV-2 M(pro) and with desirable drug-like properties, which may lead to the rapid discovery of a treatment for COVID-19.

In 2019, a novel human coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; NC_045512) [1] , spread rapidly throughout the global population with suspected human-to-human transmission via respiratory droplets [2, 3] . Most SARS-CoV-2positive individuals developed mild symptoms including upper respiratory tract illness.

However, many people with concomitant medical conditions, including pulmonary and cardiovascular disease, hypertension, diabetes mellitus, as well as older adults, have developed severe symptoms or succumbed to the virus [4, 5] . The disease, COVID-19, caused by this virus was declared a pandemic by the World Health Organization in March 2020. Over 34.4 million individuals have been infected globally so far, with a case-fatality ratio of 2.98% [6] .

SARS-CoV-2 is a 29,903 bp single-stranded RNA coronavirus [7] . It shares 82% nucleotide identity with the related, human severe acute respiratory syndrome coronavirus (SARS-CoV), and both of these viruses belong to clade b of the genus betacoronavirus [2, 3] .

Both SARS-CoV and SARS-CoV-2 have structural spike proteins anchored to the viral envelope, which recognize and bind to the host cell's membrane protease, angiotensinconverting enzyme 2 (ACE2) [3, 8, 9] . ACE2 activates the viral spike protein, allowing the virus to penetrate into the host cell [3, 10, 11] and it is expressed on the ciliated epithelial cells of the human lungs and other tissues [12] . The binding affinity of spike-ACE2 was found to be 10-20-fold higher in SARS-CoV-2 than in SARS-CoV [13] , which may be attributed to differences in the receptor-binding domain of the S1 region of the spike protein in both viruses [7] . Once inside the host cell, viral RNA is translated by the host ribosome into two polyproteins, which are proteolytically processed by coronavirus main protease (M pro ) and papain-like protease (PL pro ) [14, 15] , for assembly of new viral particles [16] . In order to J o u r n a l P r e -p r o o f molecule. This crystal structure has been regarded as the most appropriate model for performing docking studies as it is more representative of physiological conditions [22, 23] .

Previously, α-ketoamides have been synthesized to inhibit the M pro of beta-and alphacoronaviruses, although, the half-life and solubility of these compounds in plasma was unsatisfactory [19] . To increase the half-life, solubility and anti-viral activity, α-ketoamides were modified to incorporate a pyridone ring that prevents cleavage from cellular proteases [18] . These new compounds were observed to increase the plasma half-life in mice 3-fold with significantly improved kinetic plasma and thermodynamic solubilities. To identify potential binding sites, the crystal structure of SARS-CoV-2 M pro was complexed with the pyridonecontaining compound (PDB: 6Y2F) [18] . The 2-pyridone compound was bound to the shallow substrate-binding site of SARS-CoV-2 M pro containing the catalytic dyad (His- and inhibited viral activity [18] . Favorable ADMET and pharmacokinetic properties (e.g. lung tropism) and tolerability when administered subcutaneously and/or via inhalation, gave further credence for the development of 2-pyridone compounds as inhibitors of SARS-CoV-2 [18] .

Natural products and their analogues have played a significant role in the development of medicines to treat a wide variety of conditions, including infections [24] . The 2-pyridone moiety is observed in a wide variety of simple and complex organic molecules in nature.

Many organisms retain the ability to synthesize, degrade, or utilize molecules containing 2pyridone rings [25, 26] . In humans, 2-pyridone compounds have been identified as metabolites of regular cell function [27] [28] [29] . A number of 2-pyridone-containing natural products have antimicrobial, -viral, -inflammatory, -proliferative, -diabetic and -cancer properties making them attractive molecules for drug development [32] [33] [34] . The chemical properties of 2pyridones and their presence in many bioactive compounds make them a valuable resource for J o u r n a l P r e -p r o o f drug design [33, 34] . Furthermore, the 2-pyridone moiety has been shown to restrict degrees of freedom within chemical structures, while mimicking a peptide backbone [18] .

The present work was undertaken to identify potential new inhibitors of SARS-CoV-2 M pro from the trove of natural products containing a 2-pyridone scaffold. The intention of the present study is to allow for a streamlined and rapid approach in developing therapeutics towards COVID-19.

The natural products containing a 2-pyridone moiety assessed in the present study were selected through a literature search of 2-pyridone alkaloids discovered from the 1960s to present. The Chemical Abstract Service database, SciFinder (https://scifinder.cas.org), was utilized for conducting structure and keyword ("bioactive 2-pyridones", "2-pyridone alkaloids", "antimicrobial 2-pyridones", "2-pyridone natural products", "antibacterial 2pyridones" and "antifungal 2-pyridones") searches. An initial investigation provided a review from Jessen and Gademann from which a list of notable, bioactive compounds was developed [35] . Additional compounds, discovered following the publication of this review, were identified through further literature searches on compounds containing a 2-pyridone moiety.

The 2-pyridone natural products chosen for the current study were selected based on their putative antimicrobial activity. Natural products with a 2-pyridone scaffold, as well as their putative biological actions, are summarized in Appendix A Supplementary Data (Table A.1). J o u r n a l P r e -p r o o f

Due to the recently identified conformational flexibility of the SARS-CoV-2 M pro active site and the revelation of a water molecule aiding in catalysis, the room temperature, ligand-free M pro structure with an embedded water molecule has been suggested to be the most physiologically relevant crystal structure for performing molecular docking (PDB: 6WQF) [23] . Therefore, this structure was selected for in silico binding studies. The calculated binding energies and inhibition constants (K i values) for the selected 2-pyridone natural products with SARS-CoV-2 M pro were obtained using a molecular modelling procedure. This process consisted of optimization of the molecular geometry of each natural product using GaussView 5.0 [36] and docking each minimized molecular structure with a crystal structure of SARS-CoV-2 M pro (PDB: 6WQF) using AutoDock 4.2.6 software equipped with AutoDock Tools (Scripps Research Institute) [37] .

In order to minimize the molecular geometry of compounds assessed, each 2-pyridonecontaining natural product was constructed and optimized using a quantum mechanics (QM) calculation (Hartree-Fock using the 3-21G basis set) within GaussView 5.0 [36] . The minimized structure was saved as a .pdb file and was subsequently used for docking procedures.

To estimate the potential interaction and conformation of the minimized 2-pyridone natural product and SARS-CoV-2 M pro complex, a published molecular modeling procedure J o u r n a l P r e -p r o o f using AutoDock 4.2 Software was conducted [38, 39] . The published SARS-CoV-2 M pro crystal structure (PDB code: 6WQF) was obtained from the protein databank (http://www.rcsb.org/) and uploaded to UCSF Chimera (https://www.cgl.ucsf.edu/chimera/).

Water molecules were removed from this structure, except for the oxygen atom located 2.8 Å from His-41, as suggested by Kneller et al. [23] . Hydrogen atoms were added to the oxygen to complete valency of the embedded water, and the structure was saved as a .pdb file. The structure was then uploaded into AutoDock 4.2.6 and each non-polar hydrogen was merged with its bonding partner. Gasteiger partial charges for all atoms within the structure were computed and added to the enzyme. The resulting file was saved as a .pdb file.

The data from the geometry optimization of the 2-pyridone natural product was uploaded into AutoDock 4.2.6. Immediately, all non-polar hydrogen atoms were merged with their bonding partner, aromatic carbon atoms were identified, Gasteiger partial charges for all the atoms within the 2-pyridone natural product were computed and added to the molecule and bonds that could rotate were identified. The data was saved as a .pdbqt file.

Both .pdbqt files were uploaded to AutoDock and the grid maps were produced around the active site of SARS-CoV-2 M pro . The nucleophilic sulfur atom in Cys-145 (X: -16.67 Å Y: -3.63 Å Z: 12.50 Å) was located and used as the center of the grid map. The grid map size was 120 grid points × 120 grid points × 120 grid points with a grid-point spacing of 0.375 Å. The docking calculation was subsequently performed using the Lamarckian genetic algorithm [38] , and each 2-pyridone natural product was evaluated over 50 runs. The initial population size of each run was 150. During each run, the maximum number of generations simulated was 27,000, while the maximum number of energy evaluations to identify the fitness of the 2-J o u r n a l P r e -p r o o f pyridone : SARS-CoV-2 M pro interaction was 2,500,000. All predicted binding energies were calculated using a semiempirical free energy force field [38] .

The most probable docking location and the lowest binding energy predicted (∆G calc , Table 1 ) between each 2-pyridone : SARS-CoV-2 M pro complex were visualized within AutoDock. In order to quantify the performance of the docking calculation, a known procedure was used wherein each of the 50 docking runs were evaluated for repetition in the location and orientation of the ligand and placed into groups (clusters) within an all-atom root mean square deviation (RMSD) of ≤2 Å [40, 41] . The cluster data produced from each run was placed on a scatter graph to demonstrate the accuracy of the calculation for each 2- [42] . The complex with the lowest binding energy from the best cluster was saved as a .pdbqt file and evaluated using the open source visualization software, PyMOL [43] . The amino acid residues that interact with the 2-pyridone natural product, produce hydrogen bonds (H-bonds) [44, 45] J o u r n a l P r e -p r o o f

To quantify the suitability of the most favourable 2-pyridone inhibitors as drugs for SARS-CoV-2 M pro , several absorption, distribution, metabolism, excretion, and toxicity (ADMET) characteristics were calculated. The multi-parameter optimization (MPO) algorithm, was used to score the most favourable 2-pyridone compounds with the lowest calculated K i values (1-10) and estimate their theoretical ability to be used as a drug. MPO is based on six pharmacokinetic parameters: calculated partition coefficient (clogP), calculated distribution coefficient (clogD), total polar surface area (TPSA), number of H-bonding donors (HBD), acid dissociation constant (pK a ) , and molecular weight [48] . These chemical properties were calculated using their corresponding plugin and default settings in MarvinSketch (ChemAxon, https://www.chemaxon.com) [49] . pK a values were likewise determined using the default settings for macro mode and static acid/base prefix at roomtemperature (298 K). Each 2-pyridone compound was scored for a total MPO value from 0.0 -6.0 (Table 5) , where values >3.0 are considered acceptable for compounds possessing drug-like properties [48] . Theoretical aqueous solubility for compounds 1-10 were also calculated using MarvinSketch, where values >10 μg/mL are considered optimal [49, 50] . Additional ADMET properties (i.e. oral bioavailability F(20 %), acute oral toxicity (LD 50 ), and Caco-2 permeability) were generated using the ADMETLab open-source web calculator (https://admet.scbdd.com/) [51, 52] . Oral bioavailability is expressed as the fraction of drug required to achieve 20 % in systemic circulation (>20 % optimal) [53, 54] . Toxicity is expressed as mg/kg where values >500 mg/kg are considered optimal [55, 56] . Membrane permeability expressed as logP app values (m/s) for the human colorectal cell line, Caco-2 (>-5.15 cm/s is optimal) [57] . The theoretical subcellular localization of compounds 1-10, were J o u r n a l P r e -p r o o f also calculated using the admetSAR2.0 open-source web calculator (https://lmmd.educ.cn/admetsar2.0/) [58, 59] .

To display the relevance and drug-suitability of the top 2-pyridone-containing compounds investigated herein, calculated binding energies and MPO scores of the 2-pyridone compounds (K i values ≤1 μM) were compared with that of a selection of known drugs suggested for repurposing/repositioning against SARS-CoV-2 M pro ( Table 6 ). The drugs chosen for comparison were selected based on their consideration in several COVID-19-related in silico and drug repurposing studies [60] [61] [62] [63] . These known compounds offer a variety of therapeutic classes, from antivirals to neuroleptic drugs.

J o u r n a l P r e -p r o o f

From the literature search, a total of 61 natural products containing the 2-pyridone moiety were identified. The putative biological actions of many of these compounds were antimicrobial (anti-bacterial, -viral and -fungal), anti-cancer, and/or anti-proliferative or cytotoxic. Given the objective of the present study to assess potentially efficacious inhibitors of SARS-CoV-2 M pro with limited side-effects, only compounds that possessed anti-microbial properties were evaluated herein. For the putative mechanism of action of the selected compounds, see Appendix A, Supplementary Data Table A.1.

To validate the AutoDock procedure utilized in the present work, a cluster plot was J o u r n a l P r e -p r o o f

A total of 33 natural products containing the 2-pyridone moiety were docked to SARS-CoV-2 M pro using AutoDock [38, 39] . Calculated binding energies and K i values for each top- 

The ten 2-pyridone natural products (1-10) that produced the lowest K i values when complexed with SARS-CoV-2 M pro were evaluated for their fitness as potential drugs to treat COVID-19. The ADMET properties identified through the MPO score (clogP, clogD, TPSA, HBD, pK a , and molecular weight) as well as theoretical aqueous solubility, oral bioavailability F(20 %), LD 50 , subcellular localization, and membrane permeability were calculated and are shown in Table 5 

The novel coronavirus, SARS-CoV-2, has resulted in the global pandemic, COVID-19 [1] [2] [3] . This virus is highly contagious [2, 3] , more so than other coronaviruses [48] and can cause serious and potentially fatal respiratory conditions [4, 5, 49] . Currently, there are no vaccines or treatments available to combat SARS-CoV-2. As a result, a global effort has been initiated in search of a cure by repurposing or repositioning existing drugs [50, 51] . [14] [15] [16] 23] . The results of the current study show that Glu-166 was present in almost all of the 2-pyridone binding studies conducted, either as a close contact residue or as a participant in H-bonding, as shown previously [18] . This residue may therefore act as a proton donor in hydrolysis, an alternative to the embedded water molecule, to provide increased drug potency. In addition, the frequent occurrence of ligand interactions with Met-49 and Met-165 and for compounds 1-33 and His-164, Arg-188, and Gln-189 for compounds 1-13, also suggests that these residues may be important mediators in inhibitor binding to M pro . As well, almost all 2-pyridone natural products investigated in this study engaged in interactions with the catalytic dyad as proposed.

The ten top 2-pyridone-containing compounds (K i values ≤ 1.0 μM) were further evaluated on their suitability for future research as potential drugs to treat COVID-19.

ADMET properties including clogD, clogP, HBD, pK a , TPSA, aqueous solubility, oral bioavailability, acute oral toxicity, subcellular localization, and membrane permeability were calculated. The ADMET properties summarize several pharmacokinetic parameters that are considered to provide a basis on the drug-like capacity of a theoretical pharmaceutical [53] [54] [55] [56] [57] [58] [59] .

Other assessments that include ADMET parameters, such as the MPO calculation have been developed to help theorize the drug-suitability of any given compound [48] . Of the top ten 2pyridone natural products, compounds 4, 6, 7, 8, and 9 produced favourable MPO values, with leporin B (6) producing the largest MPO value (4.70). Further ADMET analysis showed that all compounds had low, but suitable aqueous solubility [50] , favourable oral bioavailability values [53, 54] , and mild to low toxicity [55, 56] . Based on the data for all ADMET parameters (Table 5) , only compound (4) was in the optimal range of all parameters, J o u r n a l P r e -p r o o f suggesting leporin A (4) may be the most suitable compound for further drug evaluation as an inhibitor of SARS-CoV-2 M pro .

Additionally, comparison of the pharmacokinetic properties of the top ten 2-pyridone natural products (K i <1 µM) with ten similar active compounds (i.e. darunavir, lopinavir, saquinavir, chlorpromazine, festinavir, oseltamivir, remdesivir, ribavirin, azithromycin, and favipiravir) tested against SARS-CoV-2 M pro [60] [61] [62] [63] showed a similar range of binding energies and MPO scores. This suggests that several of the 2-pyridone-containing compounds highlighted in this study, in addition to favourable calculated inhibitory properties against SARS-CoV-2 M pro , also exhibit comparable pharmacokinetic and drug-like profiles to those of approved therapeutics, particularly leporin A (4). These results provide further credence for the potential therapeutic value of the natural products explored herein against COVID-19, and emphasizes the further need for pre-clinical and clinical evaluation of these 2-pyridone natural products.

In summary, 33 natural products containing the 2-pyridone moiety were studied using 

Natural products are a rich source of compounds that can be utilized as therapeutics. In the context of COVID-19, natural products that are inhibitors of SARS-CoV-2 M pro may provide another avenue for combating the disease. Thirteen 2-pyridone natural products were identified to have favourable predicted inhibitory properties against the virus, five of which also exhibited favourable pharmacokinetic profiles, especially leporin A (4). The present work indicates that natural products containing a 2-pyridone scaffold have the potential to be used as therapeutics against the novel coronavirus SARS-CoV-2 to treat COVID-19. Table 1 , as well as their ADMET

properties in Table 5 . The H-bonding (dashed black lines) and close contact amino acid residues for 1-4 are depicted in their corresponding panel, as well as the catalytic dyad, His-41 (skyblue), Cys-145 (yellow), and embedded catalytic water (red/white spheres) as suggested by

Kneller et al. [23] . Figures were generated using PyMOL [43] .

J o u r n a l P r e -p r o o f

His-172, Arg-188

YM-215343

Thr-25, Leu-27, His-41, Met-49

His-41, Met-49, Cys-145, His-164, Met-165, Leu-167, Pro-168, Arg-188

His-41, Met-49, Cys-145, His-164, Met-165, Leu-167, Pro-168, Arg-188

Thr-190 (2.2)

Thr-25, Leu-27, His-41, Cys-44, Met-49, Gly-143, Cys-145, His-163, His-164

Thr-25, Leu-27, His-41

Glu-166 (2.0, 2.2, 3.3) His-41, Met-49, Phe-140, Asn-142, Ser-144, Cys-145

Ser-46, Met-49, Phe-140, Leu-141, Gly-143, Cys-145, His-163, His-164, Met-165, Leu-167

His-41, Met-49, Phe-140, Asn-142, Ser-144, Cys-145, His-163

His-163 (1.8, 2.2) His-41, Met-49, Phe-140, Leu-141, Asn-142, Gly-143, Cys-145, His-164

His-41, Met-49, Cys-145, His-163, His-164, Met-165, Leu-167, Pro-168

Cordypyridone B (8-methylpyridoxatin)

His-163 (1.8, 2.2) His-41, Met-49

Cordypyridone A (8-methylpyridoxatin)

His-163 (2.0, 2.1) His-41, Met-49

Inhibitor of mitochondrial respiratory complex II (MRC II)

His-41, Met-49, Leu-141, Asn-142, Gly-143

Ser-144, Cys-145, His-163, His-164, Met-165, Leu-167, Arg-188, Gln-189

Gln-189

His-41, Met-49, Asn-142, Gly-143, Cys-145, His-163, His-164, Met-165, Leu-167, Pro-168, Val-186

His-41, Met-49

Ser-46, Met-49, Tyr-118, Asn-119, Asn-142, Gly-143, Cys-145, Met-165, Leu-167

Leu-141, Asn-142, Gly-143, Ser-144, Cys-145, His-163, His-164

Thr-45, Met-49, Tyr-118

Gln-189 (2.7, 2.8) His-41

Asn-142 (1.8)

His-41, Met-49, Leu-141, Cys-145, His-164, Met-165, Glu-166

The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

A new coronavirus associated with human respiratory disease in China

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Prevalence of comorbidities and its effects in coronavirus disease 2019 patients: A systematic review and meta-analysis

Clinical characteristics of 140 patients infected with SARS-CoV-2 in

Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2

Structure of SARS coronavirus spike receptorbinding domain complexed with receptor

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

TISSUES 2.0: an integrative web resource on mammalian tissue expression

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Virus-encoded proteinases and proteolytic processing in the Nidovirales

From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design

Programmed ribosomal frameshifting in decoding the SARS-CoV genome

Coronavirus Main Proteinase (3CLpro) Structure: Basis for Design of Anti-SARS Drugs

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors

alpha-Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based Design

The catalysis of the SARS 3C-like protease is under extensive regulation by its extra domain

Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra αhelical domain

Structural and Evolutionary Analysis Indicate That the SARS-CoV-2 Mpro Is a Challenging Target for Small-Molecule Inhibitor Design

Structural plasticity of SARS-CoV-2 3CL Mpro active site cavity revealed by room temperature X-ray crystallography

A Historical Overview of Natural Products in Drug Discovery

Degradation of Pyridine Derivatives in Soil

Simultaneous determination of tryptophan and its 31 catabolites in mouse tissues by polarity switching UHPLC-SRM-MS

The physiological action of picolinic Acid in the human brain

N-methyl-2-pyridone-5-carboxamide (2PY)-Major Metabolite of Nicotinamide: An Update on an Old Uremic Toxin

Nicotinamide riboside is uniquely and orally bioavailable in mice and humans

Developments in the Chemistry of 2-Pyridone

Pyridones -Powerful precursors for the synthesis of alkaloids, their derivatives, and alkaloid-inspired compounds Synthesis

Bioactive Pyridone Alkaloids from a Deep-Sea-Derived Fungus Arthrinium sp. UJNMF0008, Mar Drugs

Discovery and Characterization of 4-Hydroxy-2-pyridone Derivative Sambutoxin as a Potent and Promising Anticancer Drug Candidate: Activity and Molecular Mechanism

Pyridone Alkaloids from the Leaves of Ricinus communis and Their Inhibitory Effect Against Protein Tyrosine Phosphatase 1B

4-Hydroxy-2-pyridone alkaloids: structures and synthetic approaches

Gaussian 09

Python: A Programming Language for Software Integration and Development

Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function

AutoDock4 and AutoDockTools4: Automated Docking With Selective Receptor Flexibility

Assessing energy functions for flexible docking

Comparative study of several algorithms for flexible ligand docking

An Automated Strategy for Binding-Pose Selection and Docking Assessment in Structure-Based Drug Design

The PyMOL Molecular Graphics System

An Introduction to Hydrogen Bonding

Structural Coupling Throughout the Active Site Hydrogen Bond Networks of Ketosteroid Isomerase and Photoactive Yellow Protein

Molecular docking study on anticancer activity of plant-derived natural products

Inhibitory reactivity of capsaicin with α-amylase and αglucosidase related to antidiabetes using molecular docking and quantum calculation methods

Development of broad-spectrum halomethyl ketone inhibitors against coronavirus main protease 3CL(pro)

Ligand docking and binding site analysis with PyMOL and Autodock/Vina

SARS and MERS: recent insights into emerging coronaviruses

Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review

Broad anticoronaviral activity of FDA approved drugs against SARS-CoV-2 in vitro and SARS-CoV in vivo, bioRixv

Fusapyridons A and B, Novel Pyridone Alkaloids from an Endophytic Fungus, Fusarium sp

Differential efficacy of inhibition of mitochondrial and bacterial cytochrome bc1 complexes by center N inhibitors antimycin, ilicicolin H and funiculosin

Bioactive Metabolites from a Hydrothermal Vent Fungus Aspergillus sp. YQ-13

Leporin B: a novel hexokinase II gene inducing agent from an unidentified fungus

epipyridone: tetramic acids and pyridone alkaloids from an Epicoccum sp. associated with the tree fungus Pholiota squarrosa

Apiosporamide, A 4-hydroxy-2-pyridone Alkaloid, Induces Apoptosis Via PI3K/Akt Signaling Pathway In Osteosarcoma Cells

Torrubiellone E, an antimalarial N-hydroxypyridone alkaloid from the spider pathogenic fungus Torrubiella longissima BCC 2022

Farinosones A-C, neurotrophic alkaloidal metabolites from the entomogenous deuteromycete Paecilomyces farinosus

Paeciloside A, a new antimicrobial and cytotoxic polyketide from Paecilomyces sp. strain CAFT156

YM-215343, a novel antifungal compound from Phoma sp. QN04621

Structures of cordypyridones A-D, antimalarial N-hydroxy-and N-methoxy-2-pyridones from the insect pathogenic fungus Cordyceps nipponica

Pyridovericin and pyridomacrolidin: novel metabolites from entomopathogenic fungi, Beauveria bassiana

Zumstein Georgetto Naal, In vitro anti-allergic activity of the fungal metabolite pyridovericin

Akanthomycin, a new antibiotic pyridone from the entomopathogenic fungus Akanthomyces gracilis

Characterization of the Mode of Action of Aurodox, a Type III Secretion System Inhibitor from Streptomyces goldiniensis

Isolation of 2-pyridone alkaloids from a New Zealand marine-derived penicillium species

Biosynthetic studies on the antibiotics PF1140: a novel pathway for a 2-pyridone framework

Identification and Mode of Action of a Plant Natural Product Targeting Human Fungal Pathogens

A strategy for the rapid identification of fungal metabolites and the discovery of the antiviral activity of pyrenocine a and harzianopyridone

Iterative Catalysis in the Biosynthesis of Mitochondrial Complex II Inhibitors Harzianopyridone and Atpenin B

Synthesis, antibacterial and cytotoxic evaluation of flavipucine and its derivatives

Atpenins, potent and specific inhibitors of mitochondrial complex II (succinate-ubiquinone oxidoreductase)

Pyridone and tetramic acid alkaloids from the spider pathogenic fungus Torrubiella sp. BCC 2165

tRNA Dissociation from EF-Tu after GTP Hydrolysis: Primary Steps and Antibiotic Inhibition

A small-molecule inhibitor of the bacterial type III secretion system protects against in vivo infection with Citrobacter rodentium

Amino acid and monoamine alterations in the cerebral cortex and hippocampus of mice submitted to ricinineinduced seizures

Highlights • 2-pyridone-scaffold is an inhibitory pharmacophore for SARS-CoV-2 M pro • Thirty-three natural, antimicrobial products identified with 2-pyridone moiety • All 2-pyridone natural products bind to active site of SARS-CoV-2 M pro in silico • Thirteen molecules found to have potent inhibitory activity against SARS-CoV-2 M pro • Inhibition of SARS-CoV-2 by natural 2-pyridones may

J o u r n a l P r e -p r o o f

☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.☐The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:J o u r n a l P r e -p r o o f